ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome

Journal of the American Society of Nephrology

Volumn 20, Issue 6, 2009, Pages 1404-1415

  Cattaneo, Dario ^a,c   Ruggenenti, Piero ^a,c   Baldelli, Sara ^a,c   Motterlini, Nicola ^a,b   Gotti, Eliana ^a   Sandrini, Silvio ^d   Salvadori, Maurizio ^e   Segoloni, Giuseppe ^f   Rigotti, Paolo ^c   Donati, Donato ^c   Perico, Norberto ^a,c   Remuzzi, Giuseppe ^a,b,c  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Azienda Ospedaliera Spedali Civili ^*  (Italy)

^d SPEDALI CIVILI   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ALLELE; ARTICLE; BLOOD LEVEL; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CONVALESCENCE; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXON; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MORBIDITY; NEOPLASM; PRIORITY JOURNAL; PROTEINURIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 67449097673     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008080819     Document Type: Article

References (38)

1. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729, 2004 (Pubitemid 39665325)
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342: 605-612, 2000
3. Perico N, Cattaneo D, Sayegh MH, Remuzzi G: Delayed graft function in kidney transplantation. Lancet 364: 1814-1827, 2004 (Pubitemid 39488068)
4. Marcén R, Pascual J, Teruel JL, Villafruela JJ, Rivera ME, Mampaso F, Burgos FJ, Ortuño J: Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: Is chronic allograft nephropathy the major cause of late graft loss? Transplantation 72: 57-62, 2001 (Pubitemid 32652506)
5. Andoh TF, Bennett WM: Chronic cyclosporine nephrotoxicity. Curr Opin Nephrol Hypertens 7: 265-270, 1998 (Pubitemid 28238128)
6. Schiff J, Cole E, Cantarovich M: Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2: 374-384, 2007
7. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 24: 472-495, 1993 (Pubitemid 23160616)
8. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 75: 13-33, 2004 (Pubitemid 38130115)
9. Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, Pascual M, Eap CB: Influence of MDR1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics 18: 307-315, 2008
10. Klimecki WT, Futscher BW, Grogan TM, Dalton WS: P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83: 2451-2458, 1994 (Pubitemid 24135836)
11. Tamer S, Ademoglu E, Gokkusu C, Albeniz I: Effects of cyclosporine A on deformability and oxidative stress in the peripheral lymphocytes of rats. Clin Hemorheol Microcirc 36: 75-81, 2007 (Pubitemid 46067270)
12. Nguyen NS, Pulido SM, Rüegg UT: Biphasic effects of cyclosporin A on formyl-methionyl-leucyl-phenylalanine stimulated responses in HL-60 cells differentiated into neutrophils. Br J Pharmacol 124: 1774-1780, 1998 (Pubitemid 28377112)
13. Chen C, Johnston TD, Reddy KS, Merrick JC, Mastrangelo M, Ranjan D: Cyclosporine directly causes oxidative stress and promotes Epstein- Barr virus transformation of human B cells. J Surg Res 100: 166-170, 2001 (Pubitemid 32989357)
14. Toledo-Pereyra LH, Lopez-Neblina F, Toledo AH: Reactive oxygen species and molecular biology of ischemia/reperfusion. Ann Transplant 9: 81-83, 2004
15. Thurman RG, Zhong Z, von Frankenberg M, Stachlewitz RF, Bunzendahl H: Prevention of cyclosporine-induced nephrotoxicity with dietary glycine. Transplantation 63: 1661-1667, 1997 (Pubitemid 27265511)
16. Singh D, Alexander J, Owen A, Rustom R, Bone M, Hammad A, Roberts N, Park K, Pirmohamed M: Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. Transplantation 77: 557-561, 2004 (Pubitemid 38282812)
17. Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, Pfeffer P, Hartmann A, Midtvedt K: Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation 85: 179-184, 2008 (Pubitemid 351156847)
18. Hoffmeyer S, Burk O, von Richter O, rnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478, 2000
19. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528, 2007 (Pubitemid 46175758)
20. Remuzzi G, Lesti M, Gotti E, Ganeva M, dimitrov BD, Ene-Iordache B, Gherardi G, Donati D, Salvadori M, Sandrini S, Valente U, Segoloni G, Mourad G, Federico S, Rigotti P, Sparacino V, Bosmans JL, Perico N, Ruggenenti P: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): A randomised trial. Lancet 364: 503-512, 2004
21. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, Thervet E: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14: 1889-1896, 2003 (Pubitemid 36750485)
22. Cascorbi I, Gerloff T, Johne A, et al: Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69: 169-174, 2001
23. Humar A, Ramcharan T, Kandaswamy R, Gillingham K, Payne WD, Matas AJ: Risk factors for slow graft function after kidney transplants: A multivariate analysis. Clin Transplant 16: 425-429, 2002 (Pubitemid 36004274)
24. Asderakis A, Dyer P, Augustine T, Worthington J, Campbell B, Johnson RW: Effect of cold ischemic time and HLA matching in kidneys coming from "young" and "old" donors: Do not leave for tomorrow what you can do tonight. Transplantation 72: 674-678, 2001
25. Cattaneo D, Perico N, Gaspari F, Remuzzi G: Nephrotoxic aspects of cyclosporine. Transplant Proc 36: 234S-239S, 2004 (Pubitemid 38373868)
26. Baliga R, Ueda N, Walker PD, Shah SV: Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 31: 971-997, 1999
27. Plaumann S, Blume R, Börchers S, Steinfelder HJ, Knepel W, Oetjen E: Activation of the dual-leucine-zipper-bearing kinase and induction of beta-cell apoptosis by the immunosuppressive drug cyclosporin A. Mol Pharmacol 73: 652-659, 2008
28. Kutkuhn B, Hollenbeck M, Heering P, Koch M, Voiculescu A, Reinhard T, Grabensee B: Development of insulin resistance and elevated blood pressure during therapy with cyclosporine A. Blood Press 6: 13-17, 1997 (Pubitemid 27072773)
29. Yarlagadda SG, Klein CL, Jani A: Long-term renal outcomes after delayed graft function. Adv Chronic Kidney Dis 15: 248-256, 2008 (Pubitemid 351833143)
30. Hesselink DA, van Gelder T, van Schaik RH: The pharmacogenetics of calcineurin inhibitors: One step closer toward individualized immunosuppression? Pharmacogenomics 6: 323-337, 2005 (Pubitemid 40916357)
31. Cattaneo D, Baldelli S, Perico N: Pharmacogenetics of immunosuppressants: Progress, pitfalls and promises. Am J Transplant 8: 1-10, 2008 (Pubitemid 351989490)
32. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 16: 1501-1511, 2005 (Pubitemid 41716536)
33. Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G, Ene-Iordache B, Gotti E, Donati D, Salvadori M, Sandrini S, Segoloni G, Federico S, Rigotti P, Sparacino V, Ruggenti P: Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: The MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 18: 1973-1985, 2007 (Pubitemid 46870336)
34. Gaspari F, Ferrari S, Stucchi N, Centemeri E, Carrara F, Pellegrino M, Gherardi G, Gotti E, Segoloni G, Salvadori M, Rigotti P, Valente U, Donati D, Sandrini S, Sparacino V, Remuzzi G, Perico N: Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 4: 1826-1835, 2004 (Pubitemid 39434444)
35. Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G: Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clin Transplant 10: 550-555, 1996 (Pubitemid 27010898)
36. Dharnidharka VR, Caillard S, Agodoa LY, Abbott KC: Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 81: 1662-1672, 2006 (Pubitemid 43948299)
37. Kim RB: MDR1 single nucleotide polymorphisms: Multiplicity of haplotypes and functional consequences. Pharmacogenetics 12: 425-427, 2002 (Pubitemid 34913525)
38. Fredericks S, Moreton M, Reboux S, Carter ND, Goldberg L, Holt DW, MacPhee IA: Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 82: 705-708, 2006 (Pubitemid 44395243)